The discovery of “immune checkpoints” that suppress the immune system in the tumor micro-environment has led to the development of breakthrough therapeutic antibodies exemplified by those against PD-1/PD-L1.Hongcheng is committed to discovering the therapeutic value of new checkpoints and combining targeted checkpoints with clinically proven methods such as blocking angiogenesis. On the other hand, activating the immune system is another option to overcome checkpoint blockade. Unfortunately, systemic administration of immune activation molecule is limited by immune toxicity such as cytokine storm. Therefore, we are committed to the design and engineering of immune activation molecule to achieve specificity and safety through the prodrug approach. Immune activation function can be masked until the mask is liberated in the tumor microenvironment to avoid systemic immune toxicity issues.